Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Additional Information (Detail)

v3.3.1.900
Summary of Significant Accounting Policies - Additional Information (Detail)
$ in Millions
12 Months Ended 47 Months Ended
Dec. 31, 2015
USD ($)
Segment
Dec. 31, 2015
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Property and equipment, estimated useful lives 3 years  
Reportable segment | Segment 1  
Leasehold Improvements | Minimum    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Property and equipment, estimated useful lives 4 years  
Leasehold Improvements | Maximum    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Property and equipment, estimated useful lives 6 years  
Merck KGaA    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Upfront and milestone payments received to date | $ $ 110 $ 110
Evofosfamide | Collaborative Arrangement Product Agreement | Merck KGaA    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Percentage share of eligible worldwide development expenses 70.00%